EGFR and lung cancer: Compound 68 reveals outstanding potency (IC50: 1.1–10.3 nM) against EGFR, HDAC1, and HDAC6 and promising activity (IC50: 0.71 and 7.85 μm, MTT assay) against A549 and NCI-H1975 lung cancer cell lines, and its antiproliferative activity is also superior to that of vorinostat (IC50: 2.67 and 23.76 μm) (Ding et al., 2017).